Recent developments highlight Silexion's progress in advancing SIL204 through preclinical and clinical stages, strategic collaborations, manufacturing initiatives, and financing activities to support corporate operations.

• Silexion Therapeutics attended the 7th Annual RNAi-Based Therapeutics Summit, engaging with industry stakeholders and presenting its RNAi cancer therapy developments [N1].
• The company reported positive preclinical data for SIL204 in lung cancer, advancing towards Phase 2/3 clinical trials [N2].
• Silexion completed a preclinical study expanding SIL204's application to KRAS-driven cancers [N3].
• Q1 2025 financial results were reported, highlighting key developments in RNAi cancer therapy [N4].
• Silexion entered a strategic collaboration with Catalent to advance SIL204 development for KRAS-driven cancers [N5].
• The company announced an expanded development plan for SIL204 at the NeauxCancer 2025 Conference [N6].
• 2024 financial results and progress on SIL204 for KRAS-driven cancers were reported [N7].
• Positive efficacy data for SIL204 in pancreatic cancer models were reported [N8].
• Silexion raised approximately $1 million through warrant exercises to support corporate operations [S2].
• The company initiated GMP clinical supply manufacturing of SIL204 with a leading global CDMO [S5].

Silexion's advancement of SIL204 into Phase 2/3 clinical trials for pancreatic and lung cancers, supported by positive preclinical data, strategic manufacturing collaborations, and successful capital raises, demonstrates progress in its RNAi therapeutic platform. The company's ability to secure GMP clinical supply and engage with industry stakeholders at RNAi summits reflects active execution towards clinical development milestones.

Silexion operates in a high-risk biotechnology environment with inherent uncertainties in clinical development outcomes, regulatory approvals, and market adoption. The company reported a net loss and has limited liquidity, with a current ratio of 1.0 and cash ratio below 0.6 as of March 31, 2026. Dependence on warrant exercises and financing activities to support operations may present dilution risks. The competitive landscape and scientific challenges in targeting KRAS mutations add to execution risks.

Silexion's moat is centered on its proprietary RNAi therapeutic platform targeting KRAS-driven cancers, a challenging and high-need oncology segment. Its lead candidate SIL204 has shown promising preclinical results and is advancing into clinical trials, supported by strategic partnerships for manufacturing and development. The company's focus on a difficult-to-treat mutation and its collaborations may provide competitive advantages in the RNAi oncology space, though the biotechnology sector inherently involves significant scientific and regulatory risks.

• Clinical Development Risk: Silexion's lead candidate SIL204 is in early clinical stages with inherent risks of failure in demonstrating safety and efficacy in Phase 2/3 trials.
• Financial Risk: The company reported a net loss and has limited cash reserves, relying on warrant exercises and financing to fund operations, which may lead to dilution and liquidity constraints.
• Regulatory Risk: Approval of RNAi therapeutics for oncology indications involves complex regulatory pathways with potential delays or denials.
• Market and Competitive Risk: The oncology therapeutics market is highly competitive with multiple approaches targeting KRAS mutations, posing challenges to market penetration.

• Silexion Therapeutics Corp is a Cayman Islands incorporated company with ordinary shares traded on The Nasdaq Stock Market under the ticker SLXN and warrants under SLXNW [S1].
• As of March 10, 2026, the company had 3,330,785 ordinary shares issued and outstanding [S1].
• The company is classified as an emerging growth company and a smaller reporting company [S1].
• Silexion is developing RNA interference (RNAi) therapeutics targeting KRAS-driven cancers, with its lead candidate SIL204 advancing through preclinical and clinical development stages [N2][N3][N5].
• SIL204 has completed key preclinical studies demonstrating positive efficacy in lung and pancreatic cancer models, including orthotopic pancreatic cancer models [N2][N3][N8].
• The company has entered a strategic collaboration with Catalent to advance manufacturing and development of SIL204 [N5].
• Silexion announced initiation of GMP clinical supply manufacturing of SIL204 with a leading global contract development and manufacturing organization (CDMO) [S5].
• The company has conducted multiple financing activities including warrant exercises and private placements, raising capital to support operations, including a recent $1 million raise through warrant exercises [N4][N5][N7].
• Financial snapshot as of March 31, 2026, shows cash and cash equivalents of $2.41 million, current assets of $4.07 million, current liabilities of $4.06 million, resulting in a current ratio of 1.0 and a cash ratio of 0.59 [S2].
• The company reported a net loss of $2.73 million for the quarter ended March 31, 2026, with basic and diluted earnings per share of $0.85, which may reflect accounting or non-cash items [S2].
• Management has evaluated and concluded that internal controls over financial reporting were effective as of December 31, 2025 [S1].
• Silexion has executed reverse share splits (1-for-9 and 1-for-15) and increased authorized share capital to support its capital structure [S1].
• The company is advancing SIL204 towards Phase 2/3 clinical trials for pancreatic cancer and lung cancer indications [N2].
• Silexion participates in industry events such as the 7th Annual RNAi-Based Therapeutics Summit to engage with stakeholders and present its development progress [N1].
• Risk factors disclosed in the 2025 annual report remain applicable with no material changes reported in the latest quarterly filing [S2][S12][S13].
• The company has entered into inducement agreements with warrant holders to facilitate warrant exercises at reduced prices, supporting liquidity and capital resources [S15][S16][S18].